Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients [Phase 2]
Phase 2 clinical trial update evaluating targeted drugs guided by genomic profiles in metastatic non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC [Phase 2]
Phase 2 clinical trial update on IBI-323 plus bevacizumab and platinum chemotherapy in ALK-rearranged non-small cell lung cancer, with effic…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer [EARLY_Phase 1]
Early-phase trial of a high-dose vitamin A compound in participants with resectable non-small cell lung cancer was terminated; results poste…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. [Phase 2]
A Phase 2 clinical trial evaluating serplulimab in NSCLC patients with high TPS (≥50%), conducted at a single center in Zhejiang, with outco…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating pembrolizumab with or without carboplatin and paclitaxel in recurrent or stage IIIB-IV non-small cell lung cancer h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial PROCLAIM-CX-2009 evaluating safe and active doses of CX-2009 for selected solid tumors; trial status terminated with results…
-
CLINICAL_TRIALS trial_result · 2023-12-29Clinical Trial Update: Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC [Phase 2]
Phase 2 trial update investigating neoadjuvanttislelizumab plus chemotherapy followed by surgery for unresectable stage III non-small cell l…
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating the efficacy of SIBP04 in subjects with non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study [Phase 4]
A Phase 4 clinical trial assessing the synergistic effect of elemene plus TKIs versus TKIs alone in EGFR-mutated advanced non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy [Phase 2]
Phase 2 trial evaluating adequatrelimab with bevacizumab and docetaxel in advanced non-squamous non-small cell lung cancer after progression…
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers [Phase 2]
Phase 2 trial evaluating erlotinib plus chemotherapy in TKI-resistant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study [Phase 2]
Phase 2 trial investigating anlotinib combined with docetaxel in non-driver mutation non-squamous non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) [Phase 3]
Phase 3 PEARL study evaluating durvalumab alone or chemotherapy in patients with advanced non-small cell lung cancer; results were posted in…
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) [Phase 3]
A Phase 3 trial evaluating durvalumab alone or with chemotherapy for advanced non-small cell lung cancer (NSCLC) is active/not recruiting wi…
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib [Phase 2]
Phase 2 trial investigating atezolizumab and bevacizumab in EGFR-mutant non-small cell lung cancer after progression on osimertinib; study t…
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer (Stage I).
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Stereotactic Body Radiotherapy for the Treatment of OPD [Phase 2, Phase 3]
Clinical trial update of stereotactic body radiotherapy for non-small cell lung cancer in Phase 2/Phase 3.
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy [Phase 3]
Phase 3 trial evaluating atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an…
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: BIO 300 Non-Small Cell Lung Cancer Study [Phase 1, Phase 2]
A completed Phase 1/Phase 2 trial update for BIO 300 in non-small cell lung cancer; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Her2-positive Lung Cancer Treated With Dedicated Drug [Phase 2]
A Phase 2 trial update for a HER2-positive non-small cell lung cancer treatment is reported as completed.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial update for RC48-ADC in advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Survival Prolongation by Rationale Innovative Genomics [Phase 1, Phase 2]
Phase 1/2 trial update on survival outcomes for a regimen from Rationale Innovative Genomics in metastatic and stage IIIB non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy [Phase 2]
Phase 2 clinical trial update evaluating pevonedistat with carboplatin and paclitaxel in advanced non-small cell lung cancer patients previo…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. [Phase 1]
Phase 1 trial evaluating safety and tolerability of repeated doses of an investigational drug in cancer patients with cachexia; study comple…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]
A Phase 2 trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer has completed with results posted in 2023.